Holen Sie sich die Stockscreener-App
44.42
0.57%
0.25
Vorhandelsmarkt:
44.13
-0.29
-0.65%
Schlusskurs vom Vortag:
$44.17
Offen:
$44.45
24-Stunden-Volumen:
3.56M
Relative Volume:
1.29
Marktkapitalisierung:
$11.28B
Einnahmen:
$2.32B
Nettoeinkommen (Verlust:
$782.57M
KGV:
15.96
EPS:
2.7838
Netto-Cashflow:
$875.84M
1W Leistung:
-1.14%
1M Leistung:
+1.23%
6M Leistung:
+10.03%
1J Leistung:
+11.50%
1-Tages-Spanne:
$44.13
$45.21
1-Wochen-Bereich:
$43.50
$45.41
52-Wochen-Spanne:
$33.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Firmenname
Exelixis Inc
Sektor
Branche
Telefon
(650) 837-7000
Adresse
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.42 | 11.22B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-11-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Fortgesetzt | Barclays | Equal Weight |
| 2025-09-17 | Eingeleitet | Goldman | Buy |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2024-09-19 | Eingeleitet | UBS | Neutral |
| 2024-04-11 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Eingeleitet | BTIG Research | Buy |
| 2023-12-15 | Eingeleitet | Citigroup | Buy |
| 2023-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-22 | Bestätigt | Oppenheimer | Outperform |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-09 | Eingeleitet | Wells Fargo | Overweight |
| 2023-01-26 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-11-03 | Fortgesetzt | Jefferies | Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Sell |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-18 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Eingeleitet | Goldman | Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Underweight |
| 2018-05-11 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | Needham | Buy |
| 2017-10-17 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-16 | Bestätigt | SunTrust | Buy |
| 2017-09-22 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-12 | Bestätigt | Needham | Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2017-03-31 | Eingeleitet | Needham | Buy |
| 2017-03-16 | Eingeleitet | Oppenheimer | Perform |
| 2017-02-28 | Herabstufung | Stifel | Buy → Hold |
| 2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
| 2016-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Bestätigt | Stifel | Buy |
Alle ansehen
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis Q1 2026 slides: revenue grows 10%, zanzalintinib advances - Investing.com
Exelixis Q1 Earnings Call Highlights - Yahoo Finance
Transcript : Exelixis, Inc., Q1 2026 Earnings Call, May 05, 2026 - marketscreener.com
Earnings call transcript: Exelixis beats Q1 2026 forecasts, stock rises - Investing.com
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Exelixis Posts Strong Q1 Results, Expands Share Buybacks - TipRanks
Exelixis (EXEL) Tops Q1 Earnings Estimates - Yahoo Finance
Exelixis (EXEL) Q1 2026 Earnings Transcript - The Globe and Mail
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum - ChartMill
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.58B - marketscreener.com
Exelixis Q1 Non-GAAP Earnings, Revenue Rise - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Reports Q1 Revenue $610.8M, vs. FactSet Est of $607.5M - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76 - marketscreener.com
Exelixis: Q1 Earnings Snapshot - kare11.com
Exelixis (NASDAQ: EXEL) boosts Q1 2026 earnings, cash and buybacks - Stock Titan
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can RCC franchise weather competition? - Investing.com
MSN Money - MSN
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - Caledonian Record
Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative - Yahoo Finance
Behavioral Patterns of EXEL and Institutional Flows - Stock Traders Daily
Earnings Preview: Exelixis to Report Financial Results Post-market on May 05 - Moomoo
Vanguard Capital Management (NASDAQ: EXEL) reports 5.09% stake - Stock Titan
Exelixis (EXEL) is a top-ranked value stock: Should you buy? - MSN
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC - ChartMill
Will Exelixis (EXEL) beat estimates again in its next earnings report? - MSN
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Why Exelixis (EXEL) is a top value stock for the long term - MSN
Do Options Traders Know Something About Exelixis Stock We Don't? - msn.com
Exelixis, Inc. (EXEL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings Spark Investor Interest - DirectorsTalk Interviews
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Exelixis Inc (BSP:E2XE34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Exelixis (BSP:E2XE34) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2026) - GuruFocus
BSP:E2XE34 ROE %: 45.26% — 110% Above Median - GuruFocus
Exelixis Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Exelixis Inc (BSP:E2XE34) Stock Today? - GuruFocus
Exelixis (BSP:E2XE34) Shiller PE Ratio : (As of Apr. 27, 2026) - GuruFocus
Exelixis Inc (BSP:E2XE34) Dividend - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price, Trades & News - GuruFocus
Exelixis Inc (BSP:E2XE34)Valuation Measures & Financial Statistics - GuruFocus
Exelixis Inc Stock Baskets | BSP:E2XE34 - GuruFocus
Exelixis Inc Stock Operating Data - GuruFocus
Exelixis Inc Stock Warning Signs - GuruFocus
Exelixis Inc (BSP:E2XE34) Competitors 2026 - GuruFocus
Finanzdaten der Exelixis Inc-Aktie (EXEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):